Monopar Therapeutics Inc.

US$71.42As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:MNPRHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (2.17%)
Div yield —
ROE (19.50%)
Biotechnology
Beta (5Y) 1.61
PE TTM —
TSR TTM (17.11%)
Mkt cap US$479.4M
ROIC (15.08%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$91
27.12%
(93.41%)
Hold 5|2|2|4|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.01
0.98
1.02
1.01
22.36%
5.96%
(0.50%)
0.14%
Revenue$M
24.95
25.93
26.74
26.59
2.96%
7.16%
10.79%
12.76%
Peers (US$479.4M)
Cap (US$)
PE
483.0M
—
478.7M
30.07x
Capital
TTM
5Y
10Y
Leveragex
3.104
0.040
0.035
EBIT/Intx
0.860
0.383
0.383
Own earn%
92.20
(294.80)
(262.13)
Sh yield%
13.30
28.34
28.70
Owners
Insiders/Inst%
0.25
37.96
Short interest%
1.79
SBC / revenue%
5.76
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
9–15
$1 testx
—
Incr. ROIC%
13